Trial results

$ORKA — ORKA-001; ORKA-002

Oruka Therapeutics, Inc. (ORKA) ORKA-001; ORKA-002: trial results in Moderate-to-severe psoriasis (PsO), 2026.

Research by Catalyst Intel

The catalyst

"Oruka plans to initiate Phase 3 trials of ORKA-001 in moderate-to-severe PsO in the first half of 2027, with the High Dose (600 mg), subject to regulatory interactions, and expects to report 52-week results from EVERLAST-A in December 2026. The Company also expects to report Week 16 results from the ORKA-002 Phase 2 PsO trial in the first quarter of 2027."

— Oruka Therapeutics, Inc., 8-K filed 2026-10-26 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

ORKA-ORKA001ORKA0-2026

Company

Oruka Therapeutics, Inc.

Kind

Trial results

Indication

Moderate-to-severe psoriasis (PsO)

Window

2026-12-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.